These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
98 related articles for article (PubMed ID: 26402104)
1. Histamine H3 Receptor Antagonists for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Kubo M; Kishi T; Matsunaga S; Iwata N J Alzheimers Dis; 2015; 48(3):667-71. PubMed ID: 26402104 [TBL] [Abstract][Full Text] [Related]
2. A randomized, double-blind, placebo-controlled, 16-week study of the H3 receptor antagonist, GSK239512 as a monotherapy in subjects with mild-to-moderate Alzheimer's disease. Grove RA; Harrington CM; Mahler A; Beresford I; Maruff P; Lowy MT; Nicholls AP; Boardley RL; Berges AC; Nathan PJ; Horrigan JP Curr Alzheimer Res; 2014 Jan; 11(1):47-58. PubMed ID: 24359500 [TBL] [Abstract][Full Text] [Related]
3. A randomized study of H3 antagonist ABT-288 in mild-to-moderate Alzheimer's dementia. Haig GM; Pritchett Y; Meier A; Othman AA; Hall C; Gault LM; Lenz RA J Alzheimers Dis; 2014; 42(3):959-71. PubMed ID: 25024314 [TBL] [Abstract][Full Text] [Related]
4. Protection against Brain Atrophy by Anti-dementia Medication in Mild Cognitive Impairment and Alzheimer's Disease: Meta-Analysis of Longitudinal Randomized Placebo-Controlled Trials. Kishi T; Matsunaga S; Oya K; Ikuta T; Iwata N Int J Neuropsychopharmacol; 2015 Jun; 18(12):. PubMed ID: 26091818 [TBL] [Abstract][Full Text] [Related]
5. Suvorexant for Primary Insomnia: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Kishi T; Matsunaga S; Iwata N PLoS One; 2015; 10(8):e0136910. PubMed ID: 26317363 [TBL] [Abstract][Full Text] [Related]
6. Lithium as a Treatment for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Matsunaga S; Kishi T; Annas P; Basun H; Hampel H; Iwata N J Alzheimers Dis; 2015; 48(2):403-10. PubMed ID: 26402004 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of galantamine treatment for patients with Alzheimer's disease: a meta-analysis of randomized controlled trials. Jiang D; Yang X; Li M; Wang Y; Wang Y J Neural Transm (Vienna); 2015 Aug; 122(8):1157-66. PubMed ID: 25547862 [TBL] [Abstract][Full Text] [Related]
8. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine. Rodda J; Morgan S; Walker Z Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824 [TBL] [Abstract][Full Text] [Related]
9. The safety, tolerability, pharmacokinetics and cognitive effects of GSK239512, a selective histamine H₃ receptor antagonist in patients with mild to moderate Alzheimer's disease: a preliminary investigation. Nathan PJ; Boardley R; Scott N; Berges A; Maruff P; Sivananthan T; Upton N; Lowy MT; Nestor PJ; Lai R Curr Alzheimer Res; 2013 Mar; 10(3):240-51. PubMed ID: 23521503 [TBL] [Abstract][Full Text] [Related]
10. Quantifying placebo responses in clinical evaluation of neuropsychiatric symptoms in Alzheimer's disease. Zhang N; Lv Y; Li H; Chen J; Li Y; Yin F; Li L; Zheng Q Eur J Clin Pharmacol; 2019 Apr; 75(4):497-509. PubMed ID: 30612155 [TBL] [Abstract][Full Text] [Related]
11. Meta-analysis of randomized, double-blind, placebo-controlled trials of melatonin in Alzheimer's disease. Wang YY; Zheng W; Ng CH; Ungvari GS; Wei W; Xiang YT Int J Geriatr Psychiatry; 2017 Jan; 32(1):50-57. PubMed ID: 27645169 [TBL] [Abstract][Full Text] [Related]